04 · Five things to know · 05
AbbVie took an option on AND-gated bispecifics from DISCO; Bloomberg reports Sanofi is weighing a bid for Insmed
Know it
What happened
AbbVie and DISCO Pharmaceuticals agreed on 11.19 to a research collaboration with an option to license AND-gated bispecific antibodies for solid tumors, which aim to act only on cells carrying two antigens. DISCO gets $40M upfront and is eligible for up to $2.5B in option, development and other milestones, plus royalties; targets were not disclosed. AbbVie Ventures is an existing investor in DISCO, a company in Cologne, Germany, which closed a €36M seed round in December 2025. Separately, Bloomberg reported, citing unnamed people, that Sanofi is weighing a takeover bid for Insmed. No price was reported, Insmed declined to comment, and no deal has been announced. Claim
The DISCO upfront is small next to its milestones, so most of the headline value depends on future options. A reported interest in a deal is not a deal. Analysis
Sources
Also in Five things to know
- Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients
- Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer
- Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint
- Regeneron’s Livsayis, an RNAi drug discovered by Alnylam, was approved for generalized myasthenia gravis
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know